05/04
Headlines

Omeros Corporation

Gilead Sciences GILD NASDAQ:GILD

Trending Stocks: OmniVision Technologies, Inc. (NASDAQ:OVTI), Omeros Corporation (NASDAQ:OMER), JD.Com Inc (ADR) (NASDAQ:JD), Halliburton Company (NYSE:HAL)

Kevin Long02 mins

OmniVision Technologies Inc (NASDAQ:OVTI) was upgraded by Northland Securities from a “market perform” rating to an “outperform” rating in a research note issued on Friday. The firm currently has a $28.00 price objective on the stock, up from their previous price objective of $21.00. Northland Securities’ price objective suggests a potential upside of 39.03% from…

Read More

Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)

Adam Keintzel02 mins

Cerus Corporation (NASDAQ:CERS) and a pharmaceutical unit of Nipro Corporation announced a collaboration agreement. The collaboration will lead to the development of efficient and easy-to-use disposable kit for red cells. The project will benefit from the proprietary technology of Nipro towards the creation a red cell disposable kit that suits the needs of small and…

Read More

NASDAQ Losers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Himax Technologies, Inc. (NASDAQ:HIMX), Blue Earth Inc. (NASDAQ:BBLU), Omeros Corporation (NASDAQ:OMER), Net Element International Inc (NASDAQ:NETE)

Kristen Barton03 mins

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases, announced the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University…

Read More

Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

John Bellich03 mins

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares…

Read More

Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Richard Atkins02 mins

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation…

Read More

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz03 mins

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at…

Read More